<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157154</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0150</org_study_id>
    <nct_id>NCT03157154</nct_id>
  </id_info>
  <brief_title>Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies</brief_title>
  <acronym>ERHEA</acronym>
  <official_title>Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Life expectancy of haemophilia patients (specially severe) has dramatically increase in the
      last decades, which lead to the apparition of aging diseases such as cardiovascular disease,
      with the potential bleeding risk of antiplatelet therapies and anticoagulants.

      The primary endpoint of the study is to evaluate this bleeding risk in haemophilia patients
      (all severity) with such treatment in comparison to non treated patients, according to the
      number of bleeding events in the last year reported by the haemophilia patients under study
      treatment (antiplatelet and anticoagulant) in comparison to haemophilia patients free of such
      treatment. The main hypothesis is that antiplatelet and anticoagulant therapy can be safely
      used in minor haemophilia patients but might lead to increase bleeding risk in other
      haemophilia patients.

      Secondary endpoint consist in:

        -  Evaluate the impact of know cardio-vascular risk in haemophilia patients (Odd ratios=OR)

        -  Evaluate the number of sever bleeding event in patient under study treatments compared
           to the control group

        -  Evaluate the overall consumption of factor VIII or IX supply in patients under study
           treatments compared to control group

        -  Estimate the stenosis relapse risk in haemophilia patients with arterial STENT

        -  Estimate the embolic risk of haemophilia patients with atrial fibrillation

      Population description:

      Haemophilia patients (man, all severity)

      Age above 50 years, followed during the last 5 years in one of the study centre
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeding occurrences</measure>
    <time_frame>last 12 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>First group</arm_group_label>
    <description>Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non interventional study</intervention_name>
    <description>A query form to all concerned patients by each investigating centre will be send</description>
    <arm_group_label>First group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Haemophilia patients (man, all severity)

        Age above 50 years, followed during the last 5 years in one of the study centre
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age above 50 years

          -  Hemophilia A or B carriers

          -  Followed within the 5 last years in one of the research center

        Exclusion Criteria:

          -  Jurisdictional prevention procedures

          -  Other medical condition that might interfere with the bleeding risk (Willebrand's
             disease, Other coagulation factor deficiencies, haematological malignancies, …)

          -  Other drugs that might interfere with the bleeding risk (Serotonin reuptake
             inhibitors)

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marc Trossaërt, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Trossaërt, Dr</last_name>
    <phone>02 40 08 74 68</phone>
    <email>marc.trossaert@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Desjonquères</last_name>
    <email>alexandre.desjonqueres@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BEURRIER, Dr</last_name>
      <phone>02 41 35 54 53</phone>
      <email>phbeurrier@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe BEURRIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte PAN-PETESCH, Dr</last_name>
      <phone>02 98 22 36 50</phone>
      <email>Brigitte.pan-petesch@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte PAN-PETESCH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Mans Hospital</name>
      <address>
        <city>La Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne PINEAU-VINCENT, Dr</last_name>
      <phone>02 43 43 27 78</phone>
      <email>fpineauvincent@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Fabienne PINEAU-VINCENT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne LIENHART, Dr</last_name>
      <phone>04 72 11 73 38</phone>
      <email>Anne.lienhart@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Anne LIENHART, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit GUILLET, Dr</last_name>
      <phone>02.99.28.24.10</phone>
      <email>Benoit.guillet@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit GUILLET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent ARDILLON, Dr</last_name>
      <phone>06 60 63 23 13</phone>
      <email>lardillon@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent ARDILLON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Antiplatelets</keyword>
  <keyword>Anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

